One year follow-up study of olanzapine and risperidone in the treatment of patients with first-episode schizophrenia

Zhou Hui,Jiang Kaida,Zhang Hongxia,Yang Xiaomin

DOI: https://doi.org/10.3969/j.issn.1002-0829.2008.01.010

2008-01-01

Abstract:Objective:To evaluate the efficacy and adverse reaction of olanzapine compared with risperidone in the treatment of patients with first-episode schizophrenia.Methods:This was an open-label,parallel,dose-flexible,12-months follow up study with integrated case management and naturalistic observation.Patients with first-episode schizophrenia were assigned to treatment with an initial dose of olanzapine 10mg/d(n=136)or risperidone 1mg/d(n=131).The primary efficacy measure was PANSS(Positive and Negative Syndrome Scale)tolal score,secondary efficacy measure included the relapse rate,the time from response to relapse and the time to treatment discontinuation of treatment for any reason.TESS(Treatment Emergent Symptom Scale)was used to evaluate the adverse reaction.Results:Eighty-five patients(64.9%)in risperidone group and 93 patients(68.4%)in olanzapine group completed the full follow-up study,with no statistical difference in proportion of dropouts.The response rates at the end of 12 months of risperidone group and olanzapine group were 62.6% and 69.8% respectively(P>0.05).There were no difference for the response rates between two groups at any other follow-up times.There were no difference between risperidone and olanzapine groups for the relapse rate(14.5%,12.5%,respectively),the time from response to relapse(9.5±3.8 months,9.7±3.8 months,respectively)and the time to treatment discontinuation for any reason(4.0±2.9 months,5.1±2.8 months,respectively)at the end of 12 month.Olanzapine was associated with more weight gain and risperidone with more EPS(extrapyramidal syndrome).Conclusion:Both olanzapine and risperidone were effective for patients with first-episode schizophrenia for 1 year.Olanzapine was associated with more weight gain and risperidone with more EPS.